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Background: Osteoarthritis (OA) is the most common degenerative joint disorder, and a major cause of pain and
disability among the elderly. Histone deacetylase 4 (HDAC4) has been shown to be a key regulator of chondrocyte
hypertrophy during skeletogenesis. The aims of present study were to investigate the expression of HDAC4 in
normal and OA cartilage and its potential roles during OA pathogenesis.
Methods: The knee cartilage specimen (a total of 18, 12 female and 6 male) were obtained from primary OA
patients undergoing total knee arthroplasty (TKA) and normal donors. By using immunohistochemistry staining, we
detected the expression patterns of HDAC4 in OA cartilage and normal cartilage respectively. To assess the
potential roles of HDAC4, HDAC4 expression in human chondrosarcoma cells (SW1353) was down-regulated by
transfecting small interference RNA (siRNA), thereafter, cells were treated with IL-1β or TNF-α, and the expressions
of several matrix-degrading enzymes and anabolic factors were examined by using quantitative PCR.
Results: The expression of HDAC4 was observed in the OA cartilage, whereas it was barely detected in the normal
cartilage. The extent of HDAC4 expression had a statistically negative correlation with OA severity. We further explored
that the reduction of HDAC4 level led to a significant repression of proinflammation cytokines induced up-regulated
expressions of matrix-degrading enzymes (MMP1 (Matrix metalloproteinase 1), MMP3 (Matrix metalloproteinase 3) ,
MMP13 (Matrix metalloproteinase 13), ADAMTS4 (aggrecanase 1) and ADAMTS5 (aggrecanase 2)) in SW1353 in vitro.
Moreover, knockdown of HDAC4 inhibited the expression of some anabolic genes (such as aggrecan).
Conclusions: In this study, our findings suggest that the abnormal expression of HDAC4 in osteoarthritic cartilage
might be implicated in promoting catabolic activity of chondrocyte, which is associated with OA pathogenesis. Thus,
our findings give a new insight into the mechanism of articular cartilage damage, and indicate that HDAC4 might be a
potential target for the therapeutic interventions of OA.
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Osteoarthritis (OA) is the most common joint disorder
and a major cause of pain and disability in the elderly,
which is characterized by degradation of cartilage, nar-
rowing of joint space, osteophytes formation and remodel-
ing of subchondral bone. A variety of risk factors have been
recognized to contribute to the pathogenesis of OA, such as
age, sex, primary injury, genetic predisposition, and mech-
anical factors. However, no effective disease-modifying* Correspondence: tenghj@nicemice.cn; jiangqing112@hotmail.com
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unless otherwise stated.treatment approach for OA has been developed to date.
With an accumulating number of researches into this dis-
ease, epigenetic factors have been implicated in the patho-
genesis of OA in recent years [1]. Epigenetics means
descendible phenotype changes without changes of DNA
sequences [2]. Two of the most characterized epigenetic
modifications are DNA methylation and post-translational
modification of histones. As one of the important mecha-
nisms of epigenetics, acetylating modification of histone is
controlled by histone deacetylases (HDACs). It is believed
that loss of acetylation could compact the chromatin
structure, leading to the transcriptional repression of spe-
cific genes [3].is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.biomedcentral.com/1471-2474/15/438HDACs fall into two families: the zinc-dependent classical
HDACs family, and the SIR2 family of NAD+-dependent
HDACs. The classical HDACs family has been divided into
three classes [4]: Class I HDACs (HDAC1, 2, 3 and 8) show
homology to yeast RPD3 gene, while Class II HDACs
(HDAC4, 5, 6, 7, 9 and 10) are more related to yeast
HDA1 gene [5]. HDAC11 alone represents class IV
HDACs [4].
HDAC4 has been identified to have a crucial role in
the regulation of chondrocyte hypertrophy during skele-
togenesis in mice. HDAC4-null mice displayed aberrant
chondrocyte hypertrophy and subsequent premature os-
sification in the chondrocostal cartilage [6]. Interestingly,
Trichostatin A (TSA) and sodium butyrate, acting as glo-
bal inhibitors of class I/II HDAC, have been shown to
inhibit metalloproteinase gene expression in chondro-
cytes and block cartilage resorption [7]. However, the spe-
cific HDACs involved in OA, still remain to be uncovered.
Here, we investigated the potential roles of HDAC4 in
OA pathogenesis and effects of HDAC4 on cartilage ca-
tabolism and anabolism. We found a statistically negative
relationship between HDAC4 expression level and severity
of OA. What’s more, the down-regulating of HDAC4 is
associated with the decrease of cytokine-induced matrix
catabolic genes expression. The results suggested HDAC4
may be involved in the pathogenesis of OA development




Tissue samples of knee cartilage (removed from femoral
condyle and tibial plateau) were obtained from a total of
18 donors: 17 OA donors ranging in age from 46 years
to 82 years (5 male and 12 female) and 1 normal donor
in the age of 34 years (male). Full thickness cartilage sam-
ples were harvested. All samples were graded according to
a modified Mankin score criteria [8] (Table 1), for
which 0—3 points represented normal and ≥4 points
meant OA. Osteoarthritic cartilage was collected from pa-
tients undergoing total knee arthroplasty (TKA). Normal
cartilage was harvested under the approval from ethics
committees of Medical School of Nanjing University, and
all individuals undergoing surgery were provided with full
written informed consent before the operative procedure.
Histology and immunohistochemistry
Cartilage tissues were fixed in 10% formalin immediately
after prosecuted in surgery. After that, all the cartilage
samples underwent decalcification with 15% EDTA solu-
tion for 3 weeks. Thereafter, Dehydration, clearing and
wax immersion was done, followed by paraffin embed-
ding. 5-μm thick sections were made. Hematoxylin and
eosin/safranin O staining was used to grade samples forcharacteristics of OA cartilage pathology according to a
modified Mankin score criteria (Table 1) comprising ab-
normalities of structure, cellularity variations and glycos-
aminoglycan distribution and loss. Each sample was scored
three times and the mean of the three scores was used in
any analysis done.
Indirect immunohistochemical staining was applied to
examine expression of HDAC4. Paraffin-fixed samples
were first deparaffinized in xylene and ethanol before re-
hydration in water. Next, sections were incubated in
trypsin for 30 min at 37°C and then water bath heated
in citrate sodium for 10 min. Following a wash with
phosphate-buffered saline (PBS), sections were blocked
with 0.5% bovine serum albumin (diluted in PBS) for
30 min at room temperature. HDAC4 antibody (1:200
dilution; 200 μg/ml; Santa Cruz Biotechnologies, catalog
no.sc-11418, Santa Cruz, CA, USA) and 0.5% bovine
serum albumin as a negative control were applied and in-
cubated overnight at 4°C. After rinsing with PBS, sections
were incubated with biotinylated goat anti-rabbit second-
ary antibody for 1 h (1:500 dilution; Vector Laboratories
Inc., Burlingame, CA, USA) and then incubated with
Vectastain ABC kit (PK-6100; Vector Laboratories
Inc., Burlingame, CA, USA) for 1 h at room temperature.
Finally, sections were stained with a peroxidase substrate
kit (DAB SK-4100; Vector Laboratories Inc., Burlingame,
CA, USA) and counterstained with hematoxylin.
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Sw1353 human chondrosarcoma cells were grown to con-
fluence in Dulbecco’s-modified Eagle’s medium (DMEM)
supplemented with 10% fetal calf serum (FCS), 100 units/ml
penicillin, and 100 μg/ml streptomycin. Cells were main-
tained at 37°C in an atmosphere of 5% CO2. SW1353
human chondrosarcoma cells have been widely used in re-
searches as a substitute for chondrocytes. Since siHDAC4
effect was not enough in human chondrocytes, we used
SW1353 human chondrosarcoma cells for this assay.
Small interfering RNA (siRNA)
Knockdown experiments were carried out on SW1353
human chondrosarcoma cells transfected with 10 μM
siHDAC4 (Santa Cruz Biotechnologies, catalog no.sc-
35540, Santa Cruz, CA, USA) using Lipofectamine 2000
(Invitrogen) for 48 h, following the manufacturer’s instruc-
tions. Then incubation with or without 10 ng/mL IL-1 or
10 ng/mLTNF-α for 6 h was done before cell collection.
Quantitative real time polymerase chain reaction
Total RNA was isolated from sw1353 cells using TRIzol.
First-strand cDNA was synthesized with Takara System
according to manufacturer’s protocol (Takara). RNA was
quantified spectrophotometrically based on A260 using
ND-1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA). Complementary DNA was pro-
duced using a SuperScript First-Strand Synthesis System
kit (Invitrogen). Messenger RNA expression of MMP1,
MMP3, MMP13, ADAMTS4, ADAMTS5, COL2A1 and
aggrecan was detected by real-time RT-PCR with SYBR
green detection using the ABI stepone plus real-time
PCR system (Applied Biosystems). The expression levels
of genes were defined from the threshold cycle (Ct) and
relative values were calculated by the 2-ΔΔCt method
after normalizing expression to beta-actin. Gene specific
primer sequences are shown in Table 2.
Western blotting
Cells were obtained and solubilized at 4°C with lysis buf-
fer (40 mM Tris–HCl, 150 mM NaCl, 0.5% Sodium
Deoxycholate, 1% Nonidet P40, 0.1% SDS, and protease
inhibitors), incubated on ice for 30 min and centrifuged
at 12,000 rpm for 20 min at 4°C. Protein concentrations
in lysates were determined by the BCA (bicinchoninic
acid) protein assay kit (Pierce) with bovine serum al-
bumin as the standard. Thirty micrograms of protein
extract were resolved on a 8% SDS-polyacrylamide gel,
as required and then transferred onto nitrocellulose
blotting membrane (Pall). The membranes were probed
with appropriate primary antibodies and detected using
peroxidase-conjugated anti-rabbit antibodies (1:5000) and
visualized by ECL (Pierce). The primary antibodies usedwere rabbit polyclonal anti-HDAC4 (1:500) from Santa
Cruz Biotechnology.Quantification of HDAC4 in cartilage
To assess expression and distribution of HDAC4, we
counted positive and negative cells from cartilage super-
ficial zone to the deep zone (using a Olympus BX53F
Microscope at 200× magnification). We identified super-
ficial zone (SZ), middle zone (MZ) and deep zone (DZ)
according to variations in cell morphology, cell density,
cell metabolism, and the pericellular matrix (PCM).
Chondrocytes in the SZ were characterized by their elon-
gated, flattened shape, parallel orientation to the cartilage
surface and their lack of PCM. SZ comprises the first
10–20% of full-thickness articular cartilage. The MZ
spans the next 40–60% of cartilage thickness and chon-
drocytes in this zone were of rounded shape and with an
randomly organized orientation relative to the surface. DZ
contains ellipsoid chondrocytes with an extensive PCM
and an organization of 3 or more cells in groups. The
counting was repeated 3 times for each section. The fre-
quency of positive cells was displayed as a percentage rela-
tive to the total number of cells counted in each zone.Statistical analysis
Linear regression analysis and Pearson’s correlation were
used to assess the relationship between the severity of
OA and the extent of HDAC4 expression. Unpaired t tests
were performed to determine the statistically significant
differences between two groups. All statistical analyses
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Pad Software, Inc., San Diego, CA).Results
HDAC 4 expression is upregulated in OA cartilage
To investigate the role of HDAC4 in OA pathogenesis,
we initially detected expression level of HDAC4 in hu-
man OA cartilage. Immunohistochemical study showed
a significant upregulation of HDAC4 expression in OA car-
tilage (Figure 1C, D, E and F). In OA cartilage, HDAC4-
positive cells mainly distributed in the middle zone and
deep zone, especially in chondrocyte clusters (Figure 1D, F).
Confirmed with the quantitative analysis of zonal distri-
bution of HDAC4-positive cells in 17 OA donors, signifi-
cantly more positive cells were located in deep zone than
in middle zone (Figure 2A), whereas HDAC4-positive cells
were hardly observed in superficial zone.Figure 1 Localization of HDAC4 in OA cartilage and normal cartilage.
cartilage (A). HDAC4 had significantly higher expression in OA (D,F) than in
100 μm); E,F: 200x magnification (scale bar 50 μm). Immunoreactive produHDAC4 expression decreases with increasing OA severity
There was a significant negative correlation between
‘modified’ Mankin score and HDAC4 expression deter-
mined by quantification analysis of immunohistochemis-
try. Overall, the extent of HDAC4 expression was found
to decrease linearly with the increasing severity of
OA (Figure 2B) (r = −0.49, P = 0.0041). This relation-
ship was consistent and significant both in femoral
condyle (r =−0.54, P = 0.0265) and tibial plateau (r = −0.53,
P = 0.0366).Inhibition of HDAC4 attenuates induction of catabolic
genes expression in chondrocytes
The upregulation of HDAC4 in OA cartilage suggests
the possible association of HDAC4 with OA pathogen-
esis. This led us to investigate the effect of HDAC4 on
cartilage metabolism by in vitro experiments. A definingAggrecan loss was much more severe in OA (B) than in normal
normal cartilage (C,E). A, B, C and D: 100x magnification (scale bar
cts are stained brown.
Figure 2 Statistical analyses of immunohistochemistry staining. (A) Zonal variation in HDAC4 expression in OA cartilage. The results are
expressed as mean ± SEM. (n = 17; ***P < 0.001) (B) Overall relationship between Mankin score and expression of HDAC4. The extent of HDAC4
expression decreases linearly with increasing severity of OA (n = 34, r = −0.49, P = 0.0041).
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http://www.biomedcentral.com/1471-2474/15/438feature of OA chondrocytes is their increased produc-
tion of matrix-degrading enzymes such as MMPs and
ADAMTSs. We therefore asked whether HDAC4 has ef-
fect on matrix-degrading enzymes expression. Sw1353
cells were treated with specific siRNA to block the ex-
pression of HDAC4. In our assay, we knocked down
HDAC4 expression level to less than 30% (Figure 3F).
Treatment with specific siRNA led to a significant down-
regulation of HDAC4 expression and treatment with IL-1
or TNF-α didn’t show much effect on the expression of
HDAC4 (Figure 3F). Cartilage-specific genes expression
was measured by quantitative real time polymerase chain
reaction. Expression of MMP1, MMP3, MMP13, and
ADAMTS4 was significantly upregulated after treat-
ment of chondrocytes with pro-inflammation cytokines
IL-1 or TNF-α (Figure 3). Indeed, upregulation of these en-
zymes by pro-inflammation cytokines was effectively blocked
by knockdown of HDAC4 with specific siRNA (Figure 3).
Among the HDAC4-regulated matrix-degrading enzymes,
MMP3, MMP13 and ADAMTS4 are crucial enzymes of OA
cartilage destruction. These data cumulatively demonstrate
that HDAC4 promotes catabolic activity in chondrocytes by
upregulating matrix-degrading enzymes. However, knock-
down of HDAC4 upregulated ADAMTS5 expression in the
cytokine-induced condition (Figure 3E), indicating the com-
plexity of underlying mechanism in the regulation of OA
metabolism.
In contrast to its effects on matrix-degrading enzymes,
suppression of HDAC4 decreased expression levels of both
aggrecan (Figure 4A) and COL2A1 (Figure 4B) without
the presence of cytokines. In cytokine-induced condi-
tion, HDAC4 inhibition significantly downregulated aggre-
can expression (Figure 4A), while promoted COL2A1
expression, although the extent was not large (Figure 4B).
Discussion
HDAC4 has been identified as a key regulator of chon-
drocyte hypertrophy during skeletogenesis [6]. This factdrove us to investigate the possible role HDAC may have
in the pathogenesis of OA, for chondrocyte hypertrophy
is an essential step in the process of endochondral ossifi-
cation [9], which has an important role in both cartilage
degradation and osteophytes formation. In the central
part of articular cartilage, where endochondral ossifica-
tion remains incomplete due to lack of vascularity, protein-
ases cause cartilage degradation, whilst, at the periphery of
articular cartilage, sufficient vascularity makes the process
of endochondral ossification complete and thus osteo-
phytes form [10].
In the present study, we observed that HDAC4 expres-
sion level was significantly higher in OA cartilage than
in normal cartilage by immunohistochemical staining.
The extent of HDAC4 expression had a statistically nega-
tive correlation with the severity of OA. Thus, our find-
ings give HDAC4 a link to OA, and indicate that HDAC4
may mainly contribute to the early stage OA, in which the
cartilage catabolism is more active than the end stage
OA . It is well documented that pro-inflammation cy-
tokines, such as IL-1 and TNF-α, are able to promote
the chondrocytes to produce and secrete catabolic en-
zymes which aggravate collagen breakdown and aggrecan
degradation [11]. Among them, MMP1, MMP3, MMP13
and ADAMTS4 play crucial roles in collagen degradation
and aggrecan loss [12-17]. We further explored that knock-
down of HDAC4 by specific siRNA in chondrocytes sig-
nificantly suppressed proinflammation cytokines-mediated
upregulation of matrix-degrading enzymes. These findings
indicate that HDAC4 might be involved in the pathological
process of OA.
Additionally, in our study, an especially strong HDAC4
immunostaing was observed in chondrocyte clusters and
in the deep zonal cartilage near the tidemark. Both chon-
drocyte clusters and tidemark advancement are character-
istic phenotypes of OA [18,19], moreover, chondrocyte
clusters show features of cell hypertrophy [20], and tide-
mark advancement may be partly due to the release of
Figure 3 Relative expression of key catabolic genes in the absence or presence of siHDAC4. Messenger RNA levels were quantified by real
time RT-PCR and normalized to beta-actin. The expression levels of genes (A, B, C, D and E) were defined from the threshold cycle (Ct) and
relative values were calculated by the 2-ΔΔCt method. Western blot analyses (F) were used to compare the relative levels of HDAC4 protein
with and without the treatment of siRNA ( C= control, NC =negative control). Data are presented as mean ± SEM(n = 3, in duplicate). **P < 0.01 ,***P < 0.001.
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the deep zonal articular cartilage [21]. Together with the
fact that HDAC4 controls chondrocyte hypertrophy in
chondrogenesis, it will be interesting to investigate the
possible correlation of HDAC4 with these two phenotypic
changes.
The failure of extracellular matrix (ECM) mediated by
matrix-degrading enzymes is the hallmark of OA. How-
ever, therapeutic approaches directly targeting matrix-
degrading enzymes have been proved not successful in
hauling the development of this pathological change.
Clinical trials applying MMP inhibitors as a disease-
modifying treatment have been proved unsuccessful dueto severe side effects and inefficiency of inhibiting
MMPs activity [22]. Our results suggest that specific
inhibition of HDAC4 may be an effective way to inhibit
proteinase expression. Another member from class II
HDACs, HDAC7 has been implicated to promote OA
development by upregulating MMP13 expression [23].
In the context of early embryogenesis, HDAC7 is specific-
ally expressed in the vascular endothelium and maintains
vascular integrity by myocyte enhancer factor-2 (MEF2)
mediated inhibition of MMP10 expression [24]. A recent
report [25] demonstrated that HDAC3, a class I HDAC,
regulated chondrocyte hypertrophy and matrix content
by inhibiting protein phosphatase Phlpp1 expression and
Figure 4 Relative gene expression of Aggrecan and COL2A1 in the absence or presence of siHDAC4. Messenger RNA levels were
quantified by real time RT-PCR and normalized to beta-actin. The expression levels of genes (A and B) were defined from the threshold cycle (Ct)
and relative values were calculated by the 2-ΔΔCt method. Data are presented as mean ± SEM(n = 3, in duplicate). **P < 0.01 ,***P < 0.001.
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entered the hypertrophy stage sooner. Moreover, HDAC3-
deficient chondrocytes have lower extracellular matrix pro-
duction and smaller sizes than normal chondrocytes [25].
Much work has been done with HDAC inhibitors
(HDACi) to infer the role HDACs serve in chondro-
cytes, and Trichostatin A (TSA) probably was the most
frequently applied. TSA blocked proteoglycan release
[26] and cartilage resorption [7] in cartilage explants,
suggesting the crucial roles of HDACs in the catabolism
of cartilage. TSA can also inhibit cytokine-induced metal-
loproteinases in chondrocytes [7,27]. TSA may therefore
be of therapeutic benefit in OA, and intra-articular injec-
tion of TSA into rabbits with experimental OA alleviated
the extent of cartilage erosion, concomitant with reduced
expression of IL-1 and matrix-degrading enzymes [28].
TSA also showed promise in rheumatoid arthritis (RA)
models. A daily injection of TSA for 2 weeks ameliorated
synovial inflammation and cartilage destruction in colla-
gen antibody-induced arthritis (CAIA) mice [29]. The data
in the study indicate that TSA might directly regulate
collagenase expression in chondrocytes. In addition to
broad spectrum HDACis like TSA, some isoform-selective
HDACis are utilized to investigate the role of HDACs in
chondrocytes. HDAC1 and HDAC2, both class I HDACs,
are increased in OA chondrocytes and overexpression of
them suppresses transcription of cartilage anabolic genes
such as ACAN and COL2A1 [30]. Another member of
class I HDACs, HDAC3, has recently been identified as a
regulator of chondrocyte hypertrophy and cartilage regen-
eration [25]. A recent study [31] revealed that the specific
inhibition of class I HDACs, particularly that of HDAC1,
HDAC2, and HDAC3, showed chondroprotective effect
via suppressing cytokine-induced MMP expression, show-
ing promising utilization of isoform-specific HDACis in
OA treatment strategy. With the increasing knowledge of
the structures of HDAC4 and HDAC7, more specificinhibitors of these individual isoforms could soon be
expected [32,33].
HDACis were also implicated in regulating the expres-
sion of ECM components, and the mechanism appears
to be complex. Short-term treatment of chondrocytes
(<24 hours) with HDACis promotes anabolic gene ex-
pression (e.g., COL2A1, COL9A1, COMP, and ACAN)
[30,34], however, extended treatment suppresses many
of the same transcripts [27,30,35]. The early positive ef-
fects may be the direct consequence of HDAC inhibition,
for the overexpression of HDAC1 and HDAC2 represses
the expression of ACAN and COL2A1 [30], while the
long-term blockade may be due to the elevation of inhibi-
tory factors such as Wnt-5A [35] or NAB1 [36].Conclusions
In summary, our findings support the notion that HDAC4
expression is upregulated in human OA cartilage, and in-
hibition of HDAC4 might be of benefit to prevent cartil-
age destruction in vitro by suppressing matrix-degrading
enzymes expression. These results implicate that HDAC4
is a potential pharmaceutical target in the inhibition of
cartilage destruction. It is notable that suppression of both
anabolic and catabolic activities may in fact decelerate car-
tilage turnover and thus preserve existing cartilage. Fur-
ther studies are needed to assess whether the in vitro
effects still remain when translated to in vivo models to
decelerate the progression of cartilage destruction in OA.Competing interests
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